NCT06588296: An ongoing trial by Eli Lilly and Company
This trial is ongoing. It must report results 11 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06588296 |
|---|---|
| Title | Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 24, 2024 |
| Completion date | Nov. 30, 2025 |
| Required reporting date | Nov. 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |